Holen Sie sich die Stockscreener-App
1.82
2.25%
0.04
Handel nachbörslich:
1.80
-0.02
-1.10%
Gain Therapeutics Inc Aktie (GANX) Neueste Nachrichten
Gain Therapeutics Reports Interim Data for Parkinson’s Candidate - TipRanks
GT-02287 shows biomarker, symptom stability in Gain (GANX) Parkinson’s study - Stock Titan
Gain Therapeutics says MDS-UPDRS scores remain stable after 150 days of GT-2287 treatment - marketscreener.com
Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026 - The Manila Times
Gain Therapeutics presents phase 1b data on Parkinson’s drug By Investing.com - Investing.com Canada
Gain Therapeutics presents phase 1b data on Parkinson’s drug - Investing.com
Parkinson’s patients report better smell, sleep, balance on experimental GT-02287 - Stock Titan
Bial Announces Completion of Phase 2b ACTIVATE Study with BIA 28-6156 in GBA1-Associated Parkinson’s - Yahoo Finance
Gain Therapeutics (GANX) Bounces Back: Testing Key Resistance at $1.87Overvalued Signals - Newser
Gain Therapeutics Inc. (GANX) Q1 2026 Earnings: Narrower Loss Surpasses Estimates, Stock Edges HigherSaaS Earnings Trends - Newser
Gain Therapeutics (GANX) Edges Higher as Biotech Sector Shows Mixed SignalsTrading Community Hub - Newser
3 Parkinson's Biotech Stocks Analysts Think Are Wildly Mispriced - Moomoo
Gain Therapeutics (GANX) shares edge higher after narrower-than-expected Q1 loss - MSN
GANX Technical Analysis | Trend, Signals & Chart Patterns | GAIN THERAPEUTICS INC (NASDAQ:GANX) - ChartMill
GANX Gain Therapeutics EPS beats by 26 but shares decline 27 amid revenue concernsMarket Buzz Alerts - Newser
Roth MKM Maintains Gain Therapeutics(GANX.US) With Buy Rating, Cuts Target Price to $8 - Moomoo
Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update - Black Hills Pioneer
Gain Therapeutics: Remain on Track to Begin Our Phase 2 Study in 3Q 2026 >GANX - Moomoo
Gain Therapeutics (NASDAQ: GANX) posts higher Q1 2026 loss and flags going concern risk - Stock Titan
Gain Therapeutics reports Q1 2026 net loss $5.61M; cash $16.5M; R&D and G&A rise - TradingView
Gain Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Gain Therapeutics (NASDAQ: GANX) details Q1 2026 loss and Parkinson’s trial plans - Stock Titan
Gain Therapeutics (NASDAQ:GANX) Releases Quarterly Earnings Results, Hits Expectations - MarketBeat
Gain Therapeutics beats Q1 loss estimates, shares rise 3% By Investing.com - Investing.com Canada
Gain Therapeutics (GANX) Shares Edge Higher After Narrower-Than-Expected Q1 Loss - Yahoo Finance
Gain Therapeutics: Expect to Receive FDA Clearance of Our GT-02287 IND During 2Q 2026 >GANX - Moomoo
Gain Therapeutics Q1 loss per share narrows - TradingView
Gain Therapeutics beats Q1 loss estimates, shares rise 3% - Investing.com
Gain Parkinson’s trial sees 81% biomarker drop, Phase 2 planned - Stock Titan
GANX (Gain Therapeutics) EPS beats by 26%, but shares decline 2.7% amid revenue concerns.Stock Analysis Community - Newser
Gain Therapeutics Inc expected to post a loss of 14 cents a shareEarnings Preview - TradingView
Gain Therapeutics, Inc. (NASDAQ:GANX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
3 US Biotechs Developing Parkinson’s Therapies - Sahm
[ARS] Gain Therapeutics, Inc. SEC Filing - Stock Titan
[DEF 14A] Gain Therapeutics, Inc. Definitive Proxy Statement - Stock Titan
Gain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026 - marketscreener.com
Gain Flat Ahead of Arizona Conference - Baystreet.ca
Gain Therapeutics, Inc. to Present Update on Parkinson’s Disease Drug GT-02287 at 3rd International GBA1 Meeting 2026 - Quiver Quantitative
Gain to present Parkinson’s drug update at Phoenix GBA1 meeting - Stock Titan
GANX Gain Therapeutics posts narrower Q4 2025 loss than estimates, but shares fall 2.39%.Unusual Options - Newser
GANX | Gain Therapeutics, Inc. Common Insider Trading - Quiver Quantitative
Breakout Watch: Does Gain Therapeutics Inc have a sustainable dividendMarket Risk Analysis & Fast Exit and Entry Trade Guides - baoquankhu1.vn
Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
GANX Should I Buy - Intellectia AI
Technical Analysis: Will Gain Therapeutics Inc benefit from green energy policiesQuarterly Trade Review & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Weekly Recap: Is Gain Therapeutics Inc a strong candidate for buy and holdMarket Sentiment Report & Real-Time Market Trend Scan - baoquankhu1.vn
Death Cross: Is Gain Therapeutics Inc attractive for institutional investorsPortfolio Value Report & Real-Time Stock Entry Alerts - baoquankhu1.vn
Stop Loss: What hedge funds are buying Gain Therapeutics IncInsider Selling & Long-Term Growth Stock Strategies - baoquankhu1.vn
Quarterly Trades: What hedge funds are buying Gain Therapeutics Inc2026 Spike Watch & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Gain Therapeutics Inc. (GANX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
GANX SEC FilingsGain Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):